Literature DB >> 19995921

Development of an allele-specific PCR for detection of the K65R resistance mutation in patients infected with subtype C human immunodeficiency virus type 1.

Thomas A Toni1, Bluma G Brenner, Eugene L Asahchop, Michel Ntemgwa, Daniella Moisi, Mark A Wainberg.   

Abstract

The selection of drug-resistant variants of human immunodeficiency virus type 1 (HIV-1) is an impediment to the efficiency of antiretroviral (ARV) therapy. We have developed an allele-specific real-time PCR assay to explore the presence of K65R minority species among treated HIV-1 subtype B and C infections. Thirty HIV-1 subtype C- and 26 subtype B-infected patients lacking K65R as determined by conventional sequencing methods were studied, and viral minority species were found in four HIV-1 subtype C samples.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19995921      PMCID: PMC2812128          DOI: 10.1128/AAC.01080-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  Chemoprophylaxis of HIV infection: moving forward with caution.

Authors:  Robert M Grant; Mark A Wainberg
Journal:  J Infect Dis       Date:  2006-08-29       Impact factor: 5.226

Review 2.  Update of the drug resistance mutations in HIV-1: 2007.

Authors:  Victoria A Johnson; Françoise Brun-Vézinet; Bonaventura Clotet; Huldrych F Günthard; Daniel R Kuritzkes; Deenan Pillay; Jonathan M Schapiro; Douglas D Richman
Journal:  Top HIV Med       Date:  2007 Aug-Sep

3.  In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine.

Authors:  N A Margot; J M Waters; M D Miller
Journal:  Antimicrob Agents Chemother       Date:  2006-09-18       Impact factor: 5.191

4.  Template usage is responsible for the preferential acquisition of the K65R reverse transcriptase mutation in subtype C variants of human immunodeficiency virus type 1.

Authors:  Dimitrios Coutsinos; Cédric F Invernizzi; Hongtao Xu; Daniela Moisi; Maureen Oliveira; Bluma G Brenner; Mark A Wainberg
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

5.  Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients.

Authors:  Karin J Metzner; Stefano G Giulieri; Stefanie A Knoepfel; Pia Rauch; Philippe Burgisser; Sabine Yerly; Huldrych F Günthard; Matthias Cavassini
Journal:  Clin Infect Dis       Date:  2009-01-15       Impact factor: 9.079

6.  Low-level K65R mutation in HIV-1 reverse transcriptase of treatment-experienced patients exposed to abacavir or didanosine.

Authors:  Evguenia S Svarovskaia; Nicolas A Margot; Andrew S Bae; Joshua M Waters; Derrick Goodman; Lijie Zhong; Katyna Borroto-Esoda; Michael D Miller
Journal:  J Acquir Immune Defic Syndr       Date:  2007-10-01       Impact factor: 3.731

7.  Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase.

Authors:  Urvi M Parikh; Shannon Zelina; Nicolas Sluis-Cremer; John W Mellors
Journal:  AIDS       Date:  2007-07-11       Impact factor: 4.177

8.  Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine.

Authors:  Somnuek Sungkanuparph; Weerawat Manosuthi; Sasisopin Kiertiburanakul; Nipa Saekang; Wantanit Pairoj; Wasun Chantratita
Journal:  J Clin Virol       Date:  2008-03-07       Impact factor: 3.168

9.  HIV type 1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy.

Authors:  Visva Pillay; Candice Pillay; Rami Kantor; Francois Venter; Leon Levin; Lynn Morris
Journal:  AIDS Res Hum Retroviruses       Date:  2008-11       Impact factor: 2.205

10.  Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy.

Authors:  Jeffrey A Johnson; Jin-Fen Li; Xierong Wei; Jonathan Lipscomb; David Irlbeck; Charles Craig; Amanda Smith; Diane E Bennett; Michael Monsour; Paul Sandstrom; E Randall Lanier; Walid Heneine
Journal:  PLoS Med       Date:  2008-07-29       Impact factor: 11.069

View more
  8 in total

Review 1.  Patterns of human immunodeficiency virus drug resistance mutations in people living with human immunodeficiency virus in India: A scoping review.

Authors:  Sivaraman Balaji; J Madhumathi; Aradhana Bhargava; Tanvi Singh; Nupur Mahajan; Deepti Ambalkar; Sumit Aggarwal
Journal:  Indian J Sex Transm Dis AIDS       Date:  2022-06-07

Review 2.  Are subtype differences important in HIV drug resistance?

Authors:  R J Lessells; D K Katzenstein; T de Oliveira
Journal:  Curr Opin Virol       Date:  2012-09-21       Impact factor: 7.090

3.  Low-abundance resistant mutations in HIV-1 subtype C antiretroviral therapy-naive individuals as revealed by pyrosequencing.

Authors:  Sandra Gonzalez; Damien C Tully; Clement Gondwe; Charles Wood
Journal:  Curr HIV Res       Date:  2013-01       Impact factor: 1.581

Review 4.  Past, present and future molecular diagnosis and characterization of human immunodeficiency virus infections.

Authors:  Yi-Wei Tang; Chin-Yih Ou
Journal:  Emerg Microbes Infect       Date:  2012-08-22       Impact factor: 7.163

5.  A template-dependent dislocation mechanism potentiates K65R reverse transcriptase mutation development in subtype C variants of HIV-1.

Authors:  Dimitrios Coutsinos; Cédric F Invernizzi; Daniela Moisi; Maureen Oliveira; Jorge L Martinez-Cajas; Bluma G Brenner; Mark A Wainberg
Journal:  PLoS One       Date:  2011-05-31       Impact factor: 3.240

6.  K65R in subtype C HIV-1 isolates from patients failing on a first-line regimen including d4T or AZT: comparison of Sanger and UDP sequencing data.

Authors:  Patricia Recordon-Pinson; Jennifer Papuchon; Sandrine Reigadas; Alaka Deshpande; Hervé Fleury
Journal:  PLoS One       Date:  2012-05-16       Impact factor: 3.240

7.  Extendable blocking probe in reverse transcription for analysis of RNA variants with superior selectivity.

Authors:  Tho H Ho; Kien X Dang; Susanna Lintula; Kristina Hotakainen; Lin Feng; Vesa M Olkkonen; Emmy W Verschuren; Tuomas Tenkanen; Caj Haglund; Kaija-Leena Kolho; Ulf-Hakan Stenman; Jakob Stenman
Journal:  Nucleic Acids Res       Date:  2014-11-05       Impact factor: 16.971

8.  Evaluation of the expression levels of BRAFV600E mRNA in primary tumors of thyroid cancer using an ultrasensitive mutation assay.

Authors:  Tien Viet Tran; Kien Xuan Dang; Quynh Huong Pham; Ung Dinh Nguyen; Nhung Thi Trang Trinh; Luong Van Hoang; Son Anh Ho; Ba Van Nguyen; Duc Trong Nguyen; Dung Tuan Trinh; Dung Ngoc Tran; Arto Orpana; Ulf-Håkan Stenman; Jakob Stenman; Tho Huu Ho
Journal:  BMC Cancer       Date:  2020-05-01       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.